| 1 |
Song X, You J, Shao H, Yan C. Effects of surface modification of As 2 O 3 -loaded PLGA nanoparticles on its anti-liver cancer ability: An in vitro and in vivo study. Colloids and Surfaces B: Biointerfaces 2018;169:289-97. [DOI: 10.1016/j.colsurfb.2018.05.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 2 |
Song X, Luo X, Zhang Q, Zhu A, Ji L, Yan C. Preparation and characterization of biofunctionalized chitosan/Fe3O4 magnetic nanoparticles for application in liver magnetic resonance imaging. Journal of Magnetism and Magnetic Materials 2015;388:116-22. [DOI: 10.1016/j.jmmm.2015.04.017] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 3 |
Dolgikh M. The modern creation technologies of implanted bioartificial liver. BIOMED KHIM 2010;56:425-442. [DOI: 10.18097/pbmc20105604425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 4 |
Dolgikh MS. The modern technologies for creation of implanted bioartificial liver. Biochem Moscow Suppl Ser B 2010;4:150-160. [DOI: 10.1134/s1990750810020058] [Reference Citation Analysis]
|
| 5 |
Jiang HL, Kwon JT, Kim EM, Kim YK, Arote R, Jere D, Jeong HJ, Jang MK, Nah JW, Xu CX, Park IK, Cho MH, Cho CS. Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting. J Control Release 2008;131:150-7. [PMID: 18706946 DOI: 10.1016/j.jconrel.2008.07.029] [Cited by in Crossref: 125] [Cited by in F6Publishing: 133] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 6 |
Shah O, Holmes RP, Assimos DG. Management of Patients With Hyperoxaluria. Urinary Stone Disease. [DOI: 10.1007/978-1-59259-972-1_7] [Reference Citation Analysis]
|
| 7 |
Qi P, Han J, Lu Y, Wang C, Zhu B. A transient three-plasmid expression system for the production of hepatocytes targeting retroviral vectors. Acta Biochim Biophys Sin (Shanghai) 2007;39:567-74. [PMID: 17687491 DOI: 10.1111/j.1745-7270.2007.00318.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 8 |
Jiang H, Kwon J, Kim Y, Kim E, Arote R, Jeong H, Nah J, Choi Y, Akaike T, Cho M, Cho C. Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting. Gene Ther 2007;14:1389-98. [DOI: 10.1038/sj.gt.3302997] [Cited by in Crossref: 110] [Cited by in F6Publishing: 112] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 9 |
Kim T, Jiang H, Jere D, Park I, Cho M, Nah J, Choi Y, Akaike T, Cho C. Chemical modification of chitosan as a gene carrier in vitro and in vivo. Progress in Polymer Science 2007;32:726-53. [DOI: 10.1016/j.progpolymsci.2007.05.001] [Cited by in Crossref: 255] [Cited by in F6Publishing: 174] [Article Influence: 15.9] [Reference Citation Analysis]
|
| 10 |
Park I, Kim T, Kim S, Akaike T, Cho C. Chemical Modification of Chitosan for Gene Delivery. Journal of Dispersion Science and Technology 2007;24:489-98. [DOI: 10.1081/dis-120021804] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 11 |
Wang XP, Yazawa K, Templeton NS, Yang J, Liu S, Li Z, Li M, Yao Q, Chen C, Brunicardi FC. Intravenous Delivery of Liposome-mediated Nonviral DNA Is Less Toxic than Intraperitoneal Delivery in Mice. World J Surg 2005;29:339-43. [DOI: 10.1007/s00268-004-7822-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Weiss L. Lebergentherapie: Aktueller Stand und Ausblick. Gen-Medizin 2001. [DOI: 10.1007/978-3-642-56818-3_22] [Reference Citation Analysis]
|
| 13 |
De Godoy JL, Malafosse R, Fabre M, Mitchell C, Mehtali M, Houssin D, Soubrane O. A preclinical model of hepatocyte gene transfer: the in vivo, in situ perfused rat liver. Gene Ther 2000;7:1816-23. [PMID: 11110413 DOI: 10.1038/sj.gt.3301313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 14 |
Yarmush M, Morgan J, M. Le Doux J. Gene Therapy. Electrical Engineering Handbook 1999. [DOI: 10.1201/9781420049510.ch106] [Reference Citation Analysis]
|
| 15 |
de Sousa G, Nicolas F, Placidi M, Rahmani R, Benicourt M, Vannier B, Lorenzon G, Mertens K, Coecke S, Callaerts A, Rogiers V, Khan S, Roberts P, Skett P, Fautrel A, Chesne C, Guillouzo A. A multi-laboratory evaluation of cryopreserved monkey hepatocyte functions for use in pharmaco–toxicology. Chemico-Biological Interactions 1999;121:77-97. [DOI: 10.1016/s0009-2797(99)00092-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 16 |
Duncan JR, Hicks ME, Cai SR, Brunt EM, Ponder KP. Embolization of portal vein branches induces hepatocyte replication in swine: a potential step in hepatic gene therapy. Radiology 1999;210:467-77. [PMID: 10207431 DOI: 10.1148/radiology.210.2.r99fe10467] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 17 |
Offensperger W, Thoma C, Moradpour D, von Weizsäcker F, Blum HE, Madon J. Strategies for Targeted Uptake of Antisense Oligonucleotides in Hepatocytes. Manual of Antisense Methodology 1999. [DOI: 10.1007/978-1-4615-5067-9_4] [Reference Citation Analysis]
|
| 18 |
Kichler A, Behr J, Erbacher P. Polyethylenimines. Nonviral Vectors for Gene Therapy. Elsevier; 1999. pp. 191-206. [DOI: 10.1016/b978-012358465-6/50021-9] [Cited by in Crossref: 13] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 19 |
Rolland A, Sullivan S, Petrak K. Pharmaceutical gene medicines for non-viral gene therapy. Biopharmaceuticals, an Industrial Perspective 1999. [DOI: 10.1007/978-94-017-0926-2_20] [Reference Citation Analysis]
|
| 20 |
Pieroni L, Fipaldini C, Monciotti A, Cimini D, Sgura A, Fattori E, Epifano O, Cortese R, Palombo F, La Monica N. Targeted integration of adeno-associated virus-derived plasmids in transfected human cells. Virology 1998;249:249-59. [PMID: 9791017 DOI: 10.1006/viro.1998.9332] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 21 |
Madejón A, Bartolomé J, Carreño V. In vitro inhibition of the hepatitis delta virus replication mediated by interferon and trans-ribozyme or antisense probes. J Hepatol 1998;29:385-93. [PMID: 9764984 DOI: 10.1016/s0168-8278(98)80055-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 22 |
Wu CH, Wu GY. Receptor-mediated delivery of foreign genes to hepatocytes. Adv Drug Deliv Rev 1998;29:243-8. [PMID: 10837593 DOI: 10.1016/s0169-409x(97)00082-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 23 |
Kormis KK, Wu GY. Hepatic gene therapy. Liver Growth and Repair 1998. [DOI: 10.1007/978-94-011-4932-7_24] [Reference Citation Analysis]
|
| 24 |
von Weizsäcker F, Wieland S, Köck J, Offensperger WB, Offensperger S, Moradpour D, Blum HE. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997;26:251-5. [PMID: 9252130 DOI: 10.1002/hep.510260237] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Schroff RW, Kunz LL. Targeted and Sustained-Release Delivery Concepts in Gene Therapy. Gene Transfer in the Cardiovascular System 1997. [DOI: 10.1007/978-1-4615-6277-1_9] [Reference Citation Analysis]
|
| 26 |
Bowling WM, Kennedy SC, Cai SR, Duncan JR, Gao C, Flye MW, Ponder KP. Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum Gene Ther 1996;7:2113-21. [PMID: 8934225 DOI: 10.1089/hum.1996.7.17-2113] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 27 |
Arbuthnot PB, Bralet MP, Le Jossic C, Dedieu JF, Perricaudet M, Bréchot C, Ferry N. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 1996;7:1503-14. [PMID: 8864751 DOI: 10.1089/hum.1996.7.13-1503] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 28 |
Wu J, Zern MA. Modification of liposomes for liver targeting. J Hepatol 1996;24:757-63. [PMID: 8835753 DOI: 10.1016/s0168-8278(96)80274-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 29 |
Panis Y, Rad ARK, Boyer O, Houssin D, Salzmann JL, Klatzmann D. Gene Therapy for Liver Tumors. Surgical Oncology Clinics of North America 1996;5:461-73. [DOI: 10.1016/s1055-3207(18)30395-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Schwarzenberg SJ, Sharp HL. Pediatric gastroenterology. Update on metabolic liver disease. Pediatr Clin North Am 1996;43:27-56. [PMID: 8596684 DOI: 10.1016/s0031-3955(05)70396-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 31 |
Rolland A. Controllable Gene Therapy: Recent Advances in Non-Viral Gene Delivery. Targeting of Drugs 5 1996. [DOI: 10.1007/978-1-4615-6405-8_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 32 |
Alt M, Caselmann WH. Liver-directed gene therapy: molecular tools and current preclinical and clinical studies. J Hepatol 1995;23:746-58. [PMID: 8750177 DOI: 10.1016/0168-8278(95)80044-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 33 |
Guha C, Chowdhury JR. Can a guest liver bring the gift of a gene to disarm a hostile host? Hepatology 1995;22:1888-90. [PMID: 7490004 DOI: 10.1002/hep.1840220641] [Reference Citation Analysis]
|
| 34 |
de Sousa G, Florence N, Vallès B, Coassolo P, Rahmani R. Relationships between in vitro and in vivo biotransformation of drugs in humans and animals: pharmaco-toxicological consequences. Cell Biol Toxicol 1995;11:147-53. [PMID: 8564643 DOI: 10.1007/BF00756516] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 35 |
Hara T, Aramaki Y, Takada S, Koike K, Tsuchiya S. Receptor-mediated transfer of pSV2CAT DNA to a human hepatoblastoma cell line HepG2 using asialofetuin-labeled cationic liposomes. Gene 1995;159:167-74. [PMID: 7542617 DOI: 10.1016/0378-1119(95)00100-k] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 36 |
de Verneuil H, Ged C, Boulechfar S, Moreau-Gaudry F. Porphyrias: animal models and prospects for cellular and gene therapy. J Bioenerg Biomembr 1995;27:239-48. [PMID: 7592571 DOI: 10.1007/BF02110039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 37 |
Lauer U. Hepatozytenrestringierte Gentransduktion. Molekularbiologische Grundlagen der Gastroenterologie 1995. [DOI: 10.1007/978-3-642-79782-8_41] [Reference Citation Analysis]
|
